145 related articles for article (PubMed ID: 38043556)
1. Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study.
Nkuba-Ndaye A; Dilu-Keti A; Tovar-Sanchez T; Diallo MSK; Mukadi-Bamuleka D; Kitenge R; Formenty P; Legand A; Edidi-Atani F; Thaurignac G; Pelloquin R; Mbala-Kingebeni P; Toure A; Ayouba A; Muyembe-Tamfum JJ; Delaporte E; Peeters M; Ahuka-Mundeke S;
Lancet Infect Dis; 2024 Mar; 24(3):266-274. PubMed ID: 38043556
[TBL] [Abstract][Full Text] [Related]
2. Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study.
Diallo MSK; Ayouba A; Keita AK; Thaurignac G; Sow MS; Kpamou C; Barry TA; Msellati P; Etard JF; Peeters M; Ecochard R; Delaporte E; Toure A;
Lancet Microbe; 2021 Dec; 2(12):e676-e684. PubMed ID: 35544108
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.
Mulangu S; Dodd LE; Davey RT; Tshiani Mbaya O; Proschan M; Mukadi D; Lusakibanza Manzo M; Nzolo D; Tshomba Oloma A; Ibanda A; Ali R; Coulibaly S; Levine AC; Grais R; Diaz J; Lane HC; Muyembe-Tamfum JJ; ; Sivahera B; Camara M; Kojan R; Walker R; Dighero-Kemp B; Cao H; Mukumbayi P; Mbala-Kingebeni P; Ahuka S; Albert S; Bonnett T; Crozier I; Duvenhage M; Proffitt C; Teitelbaum M; Moench T; Aboulhab J; Barrett K; Cahill K; Cone K; Eckes R; Hensley L; Herpin B; Higgs E; Ledgerwood J; Pierson J; Smolskis M; Sow Y; Tierney J; Sivapalasingam S; Holman W; Gettinger N; Vallée D; Nordwall J;
N Engl J Med; 2019 Dec; 381(24):2293-2303. PubMed ID: 31774950
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis.
McMullan LK; Flint M; Chakrabarti A; Guerrero L; Lo MK; Porter D; Nichol ST; Spiropoulou CF; Albariño C
Lancet Infect Dis; 2019 Sep; 19(9):1023-1032. PubMed ID: 31300330
[TBL] [Abstract][Full Text] [Related]
5. Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo.
Coulborn RM; Bastard M; Peyraud N; Gignoux E; Luquero F; Guai B; Bateyi Mustafa SH; Mukamba Musenga E; Ahuka-Mundeke S
Lancet Infect Dis; 2024 Jun; 24(6):602-610. PubMed ID: 38340736
[TBL] [Abstract][Full Text] [Related]
6. Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment.
Mbala-Kingebeni P; Aziza A; Di Paola N; Wiley MR; Makiala-Mandanda S; Caviness K; Pratt CB; Ladner JT; Kugelman JR; Prieto K; Chitty JA; Larson PA; Beitzel B; Ayouba A; Vidal N; Karhemere S; Diop M; Diagne MM; Faye M; Faye O; Aruna A; Nsio J; Mulangu F; Mukadi D; Mukadi P; Kombe J; Mulumba A; Villabona-Arenas CJ; Pukuta E; Gonzalez J; Bartlett ML; Sozhamannan S; Gross SM; Schroth GP; Tim R; Zhao JJ; Kuhn JH; Diallo B; Yao M; Fall IS; Ndjoloko B; Mossoko M; Lacroix A; Delaporte E; Sanchez-Lockhart M; Sall AA; Muyembe-Tamfum JJ; Peeters M; Palacios G; Ahuka-Mundeke S
Lancet Infect Dis; 2019 Jun; 19(6):648-657. PubMed ID: 31000464
[TBL] [Abstract][Full Text] [Related]
7. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
[TBL] [Abstract][Full Text] [Related]
8. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.
Tshiani Mbaya O; Mukumbayi P; Mulangu S
Front Immunol; 2021; 12():721328. PubMed ID: 34526994
[TBL] [Abstract][Full Text] [Related]
9. Field performance of three Ebola rapid diagnostic tests used during the 2018-20 outbreak in the eastern Democratic Republic of the Congo: a retrospective, multicentre observational study.
Mukadi-Bamuleka D; Bulabula-Penge J; De Weggheleire A; Jacobs BKM; Edidi-Atani F; Mambu-Mbika F; Mbala-Kingebeni P; Makiala-Mandanda S; Faye M; Diagne CT; Diagne MM; Faye O; Kajihara M; Faye O; Takada A; Sall AA; Muyembe-Tamfum JJ; van Griensven J; Ariën KK; Ahuka-Mundeke S
Lancet Infect Dis; 2022 Jun; 22(6):891-900. PubMed ID: 35298901
[TBL] [Abstract][Full Text] [Related]
10. Outbreak of Ebola virus disease in the Democratic Republic of the Congo, April-May, 2018: an epidemiological study.
Ebola Outbreak Epidemiology Team
Lancet; 2018 Jul; 392(10143):213-221. PubMed ID: 30047375
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study.
Thom R; Tipton T; Strecker T; Hall Y; Akoi Bore J; Maes P; Raymond Koundouno F; Fehling SK; Krähling V; Steeds K; Varghese A; Bailey G; Matheson M; Kouyate S; Coné M; Moussa Keita B; Kouyate S; Richard Ablam A; Laenen L; Vergote V; Guiver M; Timothy J; Atkinson B; Ottowell L; Richards KS; Bosworth A; Longet S; Mellors J; Pannetier D; Duraffour S; Muñoz-Fontela C; Sow O; Koivogui L; Newman E; Becker S; Sprecher A; Raoul H; Hiscox J; Henao-Restrepo AM; Sakoba K; Magassouba N; Günther S; Kader Konde M; Carroll MW
Lancet Infect Dis; 2021 Apr; 21(4):507-516. PubMed ID: 33065039
[TBL] [Abstract][Full Text] [Related]
13. Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection.
Rimoin AW; Lu K; Bramble MS; Steffen I; Doshi RH; Hoff NA; Mukadi P; Nicholson BP; Alfonso VH; Olinger G; Sinai C; Yamamoto LK; Ramirez CM; Okitolonda Wemakoy E; Kebela Illunga B; Pettitt J; Logue J; Bennett RS; Jahrling P; Heymann DL; Piot P; Muyembe-Tamfum JJ; Hensley LE; Simmons G
J Infect Dis; 2018 Jan; 217(2):223-231. PubMed ID: 29253164
[TBL] [Abstract][Full Text] [Related]
14. Ebola-negative neonates born to Ebola-infected mothers after monoclonal antibody therapy: a case series.
Ottoni MP; Ricciardone JD; Nadimpalli A; Singh S; Katsomya AM; Pokoso LM; Petrucci R
Lancet Child Adolesc Health; 2020 Dec; 4(12):884-888. PubMed ID: 33217357
[TBL] [Abstract][Full Text] [Related]
15. 2018 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation.
Mbala-Kingebeni P; Pratt CB; Wiley MR; Diagne MM; Makiala-Mandanda S; Aziza A; Di Paola N; Chitty JA; Diop M; Ayouba A; Vidal N; Faye O; Faye O; Karhemere S; Aruna A; Nsio J; Mulangu F; Mukadi D; Mukadi P; Kombe J; Mulumba A; Duraffour S; Likofata J; Pukuta E; Caviness K; Bartlett ML; Gonzalez J; Minogue T; Sozhamannan S; Gross SM; Schroth GP; Kuhn JH; Donaldson EF; Delaporte E; Sanchez-Lockhart M; Peeters M; Muyembe-Tamfum JJ; Alpha Sall A; Palacios G; Ahuka-Mundeke S
Lancet Infect Dis; 2019 Jun; 19(6):641-647. PubMed ID: 31000465
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo.
Hoff NA; Bratcher A; Kelly JD; Musene K; Kompany JP; Kabamba M; Mbala-Kingebeni P; Dighero-Kemp B; Kocher G; Elliott E; Reilly C; Halbrook M; Ilunga Kebela B; Gadoth A; Ngoie Mwamba G; Tambu M; McIlwain DR; Mukadi P; Hensley LE; Ahuka-Mundeke S; Rutherford GW; Muyembe-Tamfum JJ; Rimoin AW
Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35110410
[TBL] [Abstract][Full Text] [Related]
17. Immunological response to fractional-dose yellow fever vaccine administered during an outbreak in Kinshasa, Democratic Republic of the Congo: results 5 years after vaccination from a prospective cohort study.
Doshi RH; Mukadi PK; Casey RM; Kizito GM; Gao H; Nguete U B; Laven J; Sabi L; Kaba DK; Muyembe-Tamfum JJ; Hyde TB; Ahuka-Mundeke S; Staples JE
Lancet Infect Dis; 2024 Jun; 24(6):611-618. PubMed ID: 38335976
[TBL] [Abstract][Full Text] [Related]
18. Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program.
Jaspard M; Juchet S; Serra B; Mayoum B; Kanta IM; Camara MS; Mbala P; Kojan R; Malvy D
Int J Infect Dis; 2021 Dec; 113():166-167. PubMed ID: 34587535
[TBL] [Abstract][Full Text] [Related]
19. Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop.
Banadyga L; Zhu W; Kailasan S; Howell KA; Franaszek K; He S; Siragam V; Cheng K; Yan F; Moffat E; Cao W; Leung A; Embury-Hyatt C; Aman MJ; Qiu X
mBio; 2021 Jan; 12(1):. PubMed ID: 33436428
[TBL] [Abstract][Full Text] [Related]
20. Mixed-methods assessment of health and mental health characteristics and barriers to healthcare for Ebola survivors in Beni, Butembo and Katwa health zones of the Democratic Republic of Congo.
Lawry LL; Stroupe Kannappan N; Canteli C; Clemmer W
BMJ Open; 2021 Aug; 11(8):e050349. PubMed ID: 34380729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
